CKMT1A Antibody

What is CKMT1A and what are its primary cellular functions?

CKMT1A, also known as mitochondrial creatine kinase 1, is responsible for transferring high-energy phosphate from mitochondria to the cytosolic carrier creatine. It exists primarily as a peripheral membrane protein on the intermembrane side of the mitochondrial inner membrane with a molecular weight of approximately 47kDa. CKMT1A plays a crucial role in maintaining ATP levels in mitochondria, which is essential for various cellular processes including muscle contraction and energy production. Dysregulation of CKMT1A has been implicated in diseases such as mitochondrial myopathy and cardiac dysfunction, highlighting its importance in cellular health and function .

How do CKMT1A and CKMT1B differ, and does this affect antibody selection?

CKMT1A and CKMT1B are two genes located near each other on chromosome 15 that encode identical mitochondrial creatine kinase proteins. Both are referred to as CKMT1 and share the synonyms U-MtCK and mia-CK. When selecting antibodies, researchers should be aware that many commercial antibodies may not distinguish between these two proteins due to their identical amino acid sequences. For most experimental applications, this distinction is not critical, but for gene-specific studies (such as promoter analysis or transcript quantification), researchers should use nucleic acid-based detection methods with primers specific to each gene variant .

What applications are CKMT1A antibodies most commonly used for?

CKMT1A antibodies are primarily used for Western Blot (WB), Enzyme-Linked Immunosorbent Assay (ELISA), and Immunohistochemistry (IHC) applications. Other common applications include Flow Cytometry (FCM) and Immunofluorescence (IF). When selecting an antibody, researchers should verify its validation for their specific application of interest. For instance, the CKMT1A Rabbit Polyclonal Antibody (CAB5233) has been specifically validated for WB and ELISA applications with a recommended dilution of 1:500-1:2000 for Western blot .

What are the optimal conditions for detecting CKMT1A using Western blotting?

For optimal detection of CKMT1A using Western blotting, researchers should consider the following protocol guidelines:

• Sample preparation: Extract proteins using a buffer containing protease inhibitors to prevent degradation

• Gel electrophoresis: Use 10-12% SDS-PAGE gels as CKMT1A has a molecular weight of 47kDa

• Transfer: Semi-dry or wet transfer methods are both suitable

• Blocking: 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Primary antibody: Dilute CKMT1A antibody to 1:500-1:2000 in blocking buffer and incubate overnight at 4°C

• Secondary antibody: Use appropriate HRP-conjugated secondary antibody (anti-rabbit for polyclonal antibodies)

• Detection: Enhanced chemiluminescence (ECL) systems are recommended

For positive controls, mouse heart, rat heart, and rat testis samples have been validated to express detectable levels of CKMT1A protein .

How should researchers optimize immunohistochemistry protocols for CKMT1A detection in tissue samples?

Optimizing immunohistochemistry protocols for CKMT1A detection requires careful consideration of several factors:

• Fixation: 10% neutral buffered formalin is recommended for tissue fixation (12-24 hours)

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) is typically effective

• Blocking: 5-10% normal serum from the same species as the secondary antibody

• Primary antibody incubation: CKMT1A antibodies generally work well at 1:100-1:200 dilutions when incubated overnight at 4°C

• Detection system: Biotin-streptavidin or polymer-based detection systems both provide good results

• Counterstaining: Hematoxylin provides good nuclear contrast

• Controls: Include both positive controls (such as heart or testis tissue) and negative controls (primary antibody omitted)

Researchers should be aware that CKMT1A shows a mitochondrial staining pattern, typically appearing as granular cytoplasmic staining in cells with high energy demands .

What are the key considerations when using CKMT1A antibodies for studying hypoxia-related mechanisms?

When studying hypoxia-related mechanisms using CKMT1A antibodies, researchers should consider several important factors:

• Timing of hypoxia exposure: CKMT1A expression changes dynamically under hypoxic conditions, with protein levels peaking at approximately 24 hours of hypoxia exposure before declining

• HIF-1α correlation: Always measure HIF-1α levels alongside CKMT1A, as HIF-1α is a transcription factor that upregulates CKMT1A expression under hypoxia

• Hypoxia conditions: Standard conditions of 1% O₂ are commonly used, but researchers may need to optimize based on their cell type

• Controls: Include both normoxic controls and time-course analyses to capture the dynamic nature of CKMT1A expression

• Inhibitor studies: Consider using HIF-1 specific inhibitors (such as LW6) as experimental controls to confirm the HIF-1-dependent regulation of CKMT1A

• Cell viability: Monitor cell viability, as chronic hypoxia can lead to decreased cell viability which may affect protein expression levels

These considerations are particularly important for cancer research, where CKMT1A has been implicated in tumor adaptation to hypoxic microenvironments .

How can researchers effectively use CKMT1A antibodies in cancer research, particularly for NSCLC studies?

For effective use of CKMT1A antibodies in NSCLC and other cancer research, researchers should implement the following methodological approaches:

• Patient sample analysis: Use immunohistochemistry with CKMT1A antibodies to assess expression levels in tumor tissues compared to adjacent normal tissues

• Correlation with clinical parameters: Analyze CKMT1A expression in relation to pathological grade, as high CKMT1A levels have been significantly correlated with high pathological grade in NSCLC

• Functional studies: Combine antibody-based detection with siRNA knockdown experiments to investigate the functional role of CKMT1A in cancer cells

• Hypoxia adaptation studies: Design experiments that examine CKMT1A expression under both normoxic and hypoxic conditions, as hypoxia induces CKMT1A expression via HIF-1α

• EMT marker correlation: Assess the relationship between CKMT1A expression and epithelial-mesenchymal transition (EMT) markers, as CKMT1A knockdown has been shown to affect EMT in NSCLC cells

• Therapeutic potential assessment: Evaluate CKMT1A as a potential therapeutic target by analyzing the effects of its inhibition on cancer cell proliferation and invasion

Recent studies have shown that CKMT1A is highly expressed in NSCLC tissues, with 62.5% of NSCLC samples showing high expression compared to only 18.8% of adjacent normal tissues .

What are the recommended approaches for studying the interaction between CKMT1A and HIF-1α in hypoxic environments?

To effectively study the interaction between CKMT1A and HIF-1α in hypoxic environments, researchers should consider these methodological approaches:

• Time-course experiments: Monitor both HIF-1α and CKMT1A protein levels at various time points during hypoxia exposure (6, 12, 24, and 48 hours) using Western blot

• Luciferase reporter assays: Construct CKMT1A promoter-luciferase reporters to assess direct transcriptional regulation by HIF-1α

• ChIP assays: Perform chromatin immunoprecipitation to confirm HIF-1α binding to the CKMT1A promoter region

• Pharmacological inhibition: Use HIF-1 specific inhibitors (such as LW6) to confirm HIF-1-dependent regulation of CKMT1A

• Genetic manipulation: Employ HIF-1α knockdown or overexpression systems to validate the regulatory relationship

• Co-immunoprecipitation: Investigate potential protein-protein interactions between CKMT1A and components of the hypoxia response pathway

• Metabolic analyses: Combine with metabolic profiling to understand how CKMT1A-mediated changes in energy metabolism contribute to hypoxia adaptation

Research has shown that hypoxia induces an increase in both HIF-1α and CKMT1A protein expression in NSCLC cells, with CKMT1A expression peaking at 24 hours of hypoxia exposure .

How can CKMT1A antibodies be utilized in multi-parametric flow cytometry for studying mitochondrial function?

For implementing multi-parametric flow cytometry studies of mitochondrial function using CKMT1A antibodies, researchers should follow these methodological guidelines:

• Cell preparation: Permeabilize cells using gentle detergents that preserve mitochondrial integrity (such as digitonin or saponin)

• Antibody selection: Choose fluorophore-conjugated CKMT1A antibodies or use unconjugated primary antibodies with appropriate fluorescent secondary antibodies

• Multi-parameter panel design:

  • CKMT1A detection: APC-Cy7 conjugated antibodies are available for flow cytometry applications

  • Mitochondrial membrane potential: Include indicators like TMRM or JC-1

  • Reactive oxygen species: Add CellROX or MitoSOX probes

  • Mitochondrial mass: Include MitoTracker Green

• Controls: Include isotype controls and single-stained samples for compensation

• Gating strategy: Develop a hierarchical gating strategy that first identifies viable cells, then examines mitochondrial parameters

• Data analysis: Use dimensionality reduction techniques like tSNE or UMAP for complex multi-parametric data

This approach allows researchers to correlate CKMT1A expression with various parameters of mitochondrial function at the single-cell level .

How should researchers address weak or non-specific signals when using CKMT1A antibodies in Western blotting?

When encountering weak or non-specific signals with CKMT1A antibodies in Western blotting, researchers should implement this troubleshooting approach:

• Weak signal issues:

  • Increase antibody concentration: Try higher concentrations of primary antibody (e.g., 1:500 instead of 1:2000)

  • Extend incubation time: Overnight incubation at 4°C often yields better results than shorter incubations

  • Enhance detection system: Use more sensitive ECL substrates or consider switching to fluorescent detection

  • Increase protein loading: Load more total protein (50-80 μg may be necessary for low-abundance samples)

  • Check sample preparation: Ensure your lysis buffer effectively extracts mitochondrial membrane proteins

• Non-specific binding issues:

  • Optimize blocking: Try different blocking agents (5% BSA may reduce background compared to milk for phospho-specific antibodies)

  • Increase washing: Add additional or longer washing steps with 0.1% Tween-20 in TBS

  • Reduce antibody concentration: Dilute primary antibody further if multiple bands appear

  • Pre-adsorb antibody: Incubate with negative control lysates to remove cross-reactive antibodies

  • Verify antibody specificity: Consider using CKMT1A knockdown samples as negative controls

• Expected results:

  • The correct CKMT1A band should appear at approximately 47kDa

  • Positive control samples such as mouse heart, rat heart, or rat testis should show clear bands

What controls should be included when validating CKMT1A antibody specificity for research?

A comprehensive validation of CKMT1A antibody specificity should include the following controls:

• Positive expression controls:

  • Tissue controls: Heart and testis tissues consistently express high levels of CKMT1A

  • Cell line controls: Select cell lines with known CKMT1A expression (verified by RNA-seq or proteomics data)

• Negative controls:

  • Genetic knockdown: siRNA or shRNA targeting CKMT1A (verified sequence: 5′-ACGGTACCATGGCTGGTCCCTTCTCCCGT-3′)

  • CRISPR knockout: Complete absence of protein in knockout models

  • Primary antibody omission: To assess secondary antibody specificity

• Specificity controls:

  • Peptide competition: Pre-incubation of antibody with immunizing peptide should abolish specific signal

  • Multiple antibodies: Use antibodies targeting different epitopes of CKMT1A to confirm identical patterns

  • Cross-species reactivity: Test in species with known sequence homology (human, mouse, and rat show high conservation)

• Application-specific controls:

  • For IHC: Include isotype control antibodies at the same concentration

  • For IP: Include non-immune IgG from the same species

  • For IF: Include subcellular markers to confirm mitochondrial localization

This systematic approach ensures that observed signals are specifically attributable to CKMT1A rather than non-specific binding or technical artifacts .

How can researchers reconcile contradictory findings regarding CKMT1A expression levels across different experimental platforms?

When faced with contradictory findings regarding CKMT1A expression across different experimental platforms, researchers should implement this methodological approach:

• Technical assessment:

  • Antibody validation: Verify that all antibodies used recognize the same epitope region of CKMT1A

  • Platform-specific limitations: Acknowledge inherent differences in sensitivity between techniques (e.g., WB vs. IHC vs. qPCR)

  • Sample preparation differences: Different extraction methods may yield varying protein recovery efficiency

• Biological considerations:

  • Isoform specificity: Ensure methods distinguish between CKMT1A and highly similar proteins like CKMT1B

  • Post-translational modifications: Some antibodies may be sensitive to phosphorylation or other modifications

  • Temporal dynamics: CKMT1A expression changes dynamically under stress conditions (e.g., peaks at 24h of hypoxia)

• Reconciliation strategies:

  • Multi-method validation: Confirm important findings using orthogonal methods (e.g., protein and mRNA level measurements)

  • Targeted mass spectrometry: Use as a gold standard for absolute quantification

  • Single-cell analysis: Determine if population heterogeneity explains discrepancies

  • Functional validation: Use knockdown/overexpression to confirm biological relevance despite quantitative differences

• Data integration approach:

  Method	Sensitivity	Specificity	Quantitative	Spatial Information	Recommended Use
  WB	High	Medium	Semi	No	Protein size verification
  qPCR	Very High	High	Yes	No	Transcript levels
  IHC	Medium	Medium	Semi	Yes	Tissue localization
  ELISA	High	High	Yes	No	Protein quantification
  FC	Medium	Medium	Yes	No	Cell population analysis

By systematically comparing results across these platforms and understanding their inherent limitations, researchers can develop a more comprehensive understanding of CKMT1A biology .

How should researchers design experiments to investigate CKMT1A's role in cancer progression and hypoxia adaptation?

To effectively investigate CKMT1A's role in cancer progression and hypoxia adaptation, researchers should design experiments following these methodological guidelines:

• Expression analysis in clinical samples:

  • Compare CKMT1A expression in tumor vs. adjacent normal tissues using IHC

  • Correlate expression levels with clinical parameters (pathological grade, stage, patient survival)

  • Use RT-qPCR with primers (F: 5′-CTTCACCTCACTTTACCTTC-3′, R: 5′-TCTTTTACTTCTCTGCGTCT-3′) to quantify mRNA levels

• Functional studies in cell models:

  • Knockdown CKMT1A using validated siRNA sequences

  • Assess effects on cell proliferation (CCK8 assay, colony formation)

  • Evaluate cell invasion capability (transwell assays)

  • Examine epithelial-mesenchymal transition markers (E-cadherin, vimentin)

• Hypoxia adaptation experiments:

  • Expose cells to 1% O₂ conditions for various durations (6, 12, 24, 48 hours)

  • Monitor HIF-1α and CKMT1A protein levels by Western blot

  • Use HIF-1 specific inhibitors (e.g., 10 μM LW6) to confirm pathway dependency

  • Assess whether CKMT1A knockdown affects cellular response to hypoxia

• Mechanistic investigations:

  • Analyze CKMT1A promoter for HIF-1 binding sites

  • Perform luciferase reporter assays to confirm transcriptional regulation

  • Investigate metabolic alterations using seahorse analysis or metabolomics

  • Assess mitochondrial function (membrane potential, ROS production)

Research has demonstrated that CKMT1A is highly expressed in NSCLC tissues, with 62.5% of samples showing high expression compared to only 18.8% of adjacent normal tissues. Furthermore, hypoxia has been shown to induce CKMT1A expression via HIF-1α, and knockdown of CKMT1A inhibits cell proliferation and invasion, which can be partially rescued by hypoxia .

What are the key considerations when evaluating CKMT1A as a potential biomarker for cancer diagnosis or prognosis?

When evaluating CKMT1A as a potential biomarker for cancer diagnosis or prognosis, researchers should address these critical methodological considerations:

• Sample selection and statistical power:

  • Include adequate sample sizes (minimum 30-50 samples per group)

  • Ensure proper matching of case-control cohorts for age, sex, and other relevant factors

  • Consider tissue microarrays for efficient screening of large sample sets

• Detection methodology standardization:

  • Establish consistent IHC scoring systems (e.g., H-score or percentage of positive cells)

  • Validate antibody specificity in the specific tissue type being studied

  • Consider automated image analysis for objective quantification

• Clinical correlation analysis:

  • Correlate CKMT1A expression with established prognostic factors

  • Perform multivariate analysis to determine independent prognostic value

  • Conduct Kaplan-Meier survival analysis with appropriate statistical tests

• Biomarker performance assessment:

  • Calculate sensitivity, specificity, positive and negative predictive values

  • Determine receiver operating characteristic (ROC) curves and area under curve (AUC)

  • Compare performance against existing biomarkers

• Multi-marker panel approach:

  • Evaluate CKMT1A in combination with other markers for improved performance

  • Consider integrating with clinical parameters for comprehensive risk assessment

  • Develop and validate predictive algorithms

Current evidence suggests CKMT1A has potential as a biomarker, particularly in NSCLC where high CKMT1A expression correlates significantly with high pathological grade. The significant difference in expression between tumor (62.5% high expression) and normal tissues (18.8% high expression) supports its diagnostic potential .